ArticleCurrent oncology (Toronto, Ont.)2020

Reevaluating Patient Eligibility for Inotuzumab Ozogamicin Based on CD22 Expression: Is Dim Expression Sufficient?

Warren Fingrut et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.